A股異動 | 三諾生物(300298.SZ)大漲超14% 續為睿遠成長價值混合基金重倉股
格隆匯1月22日丨三諾生物(300298.SZ)高開高走,現報39.87元,漲14.47%,暫成交2億元,最新總市值225億元。明星基金經理傅鵬博管理的睿遠成長價值混合基金昨日披露其四季報,根據報吿,截至四季度末,該基金的股票倉位為89.04%。其中,三諾生物位居其前十大重倉股的第七位,持倉數量為2707.5萬股,佔基金淨值比為3.17%。此外值得關注的是,在該基金此前公佈的三季報中,三諾生物位居其前十大重倉股的第四位,持倉數量為2509.5萬股,佔基金淨值比為4.64%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.